Coronary artery stenting and eptifibatide treatment in diabetes
Publication
, Journal Article
McLellan, CS; O'Shea, JC; Tcheng, JE; Labinaz, M
Published in: Cardiology Review
April 1, 2004
We evaluated data from the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial regarding the outcomes of diabetic patients using eptifibatide, a small molecule glycoprotein IIb/IIIa inhibitor. Eptifibatide treatment during nonurgent coronary stent implantation was associated with a similar relative reduction in adverse ischemic complications in both diabetic and nondiabetic patients.
Duke Scholars
Published In
Cardiology Review
ISSN
1092-6607
Publication Date
April 1, 2004
Volume
21
Issue
4
Related Subject Headings
- Cardiovascular System & Hematology
Citation
APA
Chicago
ICMJE
MLA
NLM
McLellan, C. S., O’Shea, J. C., Tcheng, J. E., & Labinaz, M. (2004). Coronary artery stenting and eptifibatide treatment in diabetes. Cardiology Review, 21(4).
McLellan, C. S., J. C. O’Shea, J. E. Tcheng, and M. Labinaz. “Coronary artery stenting and eptifibatide treatment in diabetes.” Cardiology Review 21, no. 4 (April 1, 2004).
McLellan CS, O’Shea JC, Tcheng JE, Labinaz M. Coronary artery stenting and eptifibatide treatment in diabetes. Cardiology Review. 2004 Apr 1;21(4).
McLellan, C. S., et al. “Coronary artery stenting and eptifibatide treatment in diabetes.” Cardiology Review, vol. 21, no. 4, Apr. 2004.
McLellan CS, O’Shea JC, Tcheng JE, Labinaz M. Coronary artery stenting and eptifibatide treatment in diabetes. Cardiology Review. 2004 Apr 1;21(4).
Published In
Cardiology Review
ISSN
1092-6607
Publication Date
April 1, 2004
Volume
21
Issue
4
Related Subject Headings
- Cardiovascular System & Hematology